What Гинофорт Treats: Main Uses and Benefits

Гинофорт is commonly used in addressing Vulvovaginal Candidiasis (VVC), an infection often caused by Candida species. Its use is aligned with treating this condition, and Butoconazole is applied for the local management of VVC. The medicine plays a role in managing symptoms related to inflammatory or irritative states, such as vulvovaginal itching (pruritus), noticeable burning, and local discomfort. This supportive action contributes to improved comfort during periods of heightened symptoms. The treatment is relevant for managing symptoms that interfere with daily comfort.

It is commonly used across conditions presenting with acute episodes of VVC and may be part of symptomatic management for patients experiencing recurrent manifestations. The primary therapeutic applications include treating acute episodes, managing the symptomatic manifestations of recurrent VVC, and addressing infections confirmed to be caused by susceptible Candida species. This therapy may assist with maintaining functional stability and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Vulvovaginal Discomfort

Property	Description
Primary Therapeutic Domain	Local management of Vulvovaginal Candidiasis
Symptom Focus	Symptoms related to physical discomfort, such as itching and burning
Condition Categories	Conditions presenting with acute or recurrent episodes
Therapeutic Benefit	Provides support that helps ease the overall symptom burden

---

Regulatory References

1. NIH DailyMed drug label

The eligibility for using Гинофорт (butoconazole nitrate) is officially defined by specific contraindications and patient status constraints.

Contraindications and Exclusions

Classification	Population/Status
Contraindicated	Patients with a known history of hypersensitivity or allergy to butoconazole nitrate or any of the product's excipients/components.
Safety Not Established	Children (Pediatric use) – safety and effectiveness have not been formally established.
Restricted Use	Pregnant women (Pregnancy Category C) – use is only advised if the potential benefit is judged to outweigh the potential risk to the fetus.
Caution Advised	Nursing Mothers – it is not known whether the drug is excreted in human milk, thus caution should be exercised when administered to a breastfeeding woman.

Eligibility-Related Restrictions

The formulation contains mineral oil, which may weaken latex or rubber products such as condoms or vaginal diaphragms. Therefore, use of such products for contraception or barrier protection is not recommended for 72 hours following treatment with this cream.

Regulatory documentation establishes that use is allowed for non-pregnant women without a history of hypersensitivity to the drug's components. All other populations, including those with certain physiological states or co-use of specific contraceptive methods, are subject to formal contraindications, use restrictions, or cautionary statements based on regulatory findings.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Butoconazole Nitrate cream, strictly based on regulatory labeling and government health authority information. Due to the local, intravaginal route of administration, systemic absorption of the active ingredient is minimal.

Documented Physical Interactions

The official interaction profile is structured around a physical substance interaction rather than systemic drug-drug interactions. The cream formulation contains mineral oil as a non-medicinal component, which can physically compromise the integrity of certain medical devices.

Interaction Type	Affected Products	Official Restriction
Physical weakening of material	Latex or rubber condoms	Use is not recommended for 72 hours (3 days) after treatment.
Physical weakening of material	Vaginal contraceptive diaphragms	Use is not recommended for 72 hours (3 days) after treatment.

This interaction stems from the physical effect of the mineral oil excipient, which is documented to weaken the material structure of products made from latex or rubber, potentially leading to device failure. Regulatory labeling therefore mandates a timing-based separation rule of 72 hours for these products.

Systemic Interaction Profile

No official documentation exists for systemic drug-drug interactions, metabolic interactions (e.g., involving CYP enzymes), or interactions with food, alcohol, or herbal products. The absence of these warnings reflects the medicine's minimal systemic exposure.

The mechanism of action centers on its active component, butoconazole, which interferes directly with the fundamental life processes of fungal cells. This leads to a targeted physiological consequence that results in the clearance of fungal cells.

Targeted Blockade of Fungal Sterol Synthesis

The drug's primary action is the inhibition of a specific fungal enzyme: lanosterol 14alpha-demethylase (CYP51). This enzyme is essential for creating ergosterol, the main structural component of the fungal cell membrane. By binding to and blocking this enzyme, the drug prevents the synthesis of essential structural components, initiating fungal cell lysis.

Disruption of Fungal Cell Membrane Integrity

Preventing ergosterol synthesis causes two key physiological consequences: essential sterols are depleted, and toxic, structurally-flawed sterols accumulate within the fungal cell membrane. This dual action destabilizes the membrane, significantly increasing its permeability and causing the leakage of vital internal components. The resulting breakdown of fungal cells leads to the destruction of fungal cells and reduction of the organism load in the local environment, which is the key physiological consequence of this mechanistic cascade.

How to Use Гинофорт (Butoconazole Nitrate)

The usage of Butoconazole Nitrate 2% Vaginal Cream is structured around a single-dose, short-term treatment protocol designed for intravaginal administration. The medicine is classified as a bioadhesive formulation, meaning it is designed to adhere to the application site to allow for a sustained release of the active ingredient over a period of up to 72 hours.

---

Official Dosing and Administration

The approved route of administration is strictly intravaginal.

Usage Parameter	Official Instruction
Standard Adult Dose	One applicatorful of the 2% cream (approximately 5 grams or 100 mg Butoconazole Nitrate).
Frequency	Single-dose application (one time).
Timing	Typically administered at bedtime to optimize retention and sustained release.
Delivery Method	Use the prefilled, disposable applicator provided with the product to ensure proper dosage.

---

Contextual Use Requirements

Official labeling includes key instructions necessary for proper use. The cream contains components, such as mineral oil, that may compromise the integrity of certain materials. Therefore, the use of latex or rubber barrier contraceptives (such as condoms or diaphragms) is not advised for 72 hours following the administration of the cream.

While the single application is the standard for non-pregnant adults, some clinical guidelines recommend a prolonged regimen for specific groups. For example, Butoconazole may be administered as a once-daily regimen for 7 consecutive days for pregnant women in the second and third trimesters. For all other adult populations, no specific dosage adjustments are typically noted for conditions like renal or hepatic impairment.

Research Evidence / Overview of Studies for Гинофорт

---

Evidence for Treating Vaginal Candidiasis (Yeast Infection)

This section will summarize the available clinical trial evidence and supporting research that has investigated the use of Гинофорт (butoconazole) specifically for its approved indication, focusing on how these studies measured the outcomes and safety profile.

Research has evaluated Гинофорт in studies focused on the treatment of vaginal candidiasis, a condition characterized by inflammatory or irritative states and symptoms that may vary in intensity. The findings describe patterns observed in the studies that evaluated Гинофорт in research for this condition. The research reports changes measured during the study period in terms of patient-reported outcomes describing perceived discomfort.

---

Evidence for Treating Recurrent or Complicated Vaginal Candidiasis

Some studies have explored how Гинофорт performs in cases described as conditions characterized by fluctuating or episodic manifestations or when initial treatment was associated with limited success. These scenarios involve periods of heightened symptoms and were evaluated in research settings with varying symptom burdens. The data gathered in these settings typically has examined outcomes reflecting daily functioning or activity level during the study period and follow-up. However, the data for certain groups remain insufficient.

---

Long-term Studies and Follow-up

Research related to long-term outcomes for topical treatments like Гинофорт is often subject to certain limitations. Studies primarily provide research exploring short-term symptom changes, meaning that follow-up durations were limited in many of the initial trials. Long-term effects are not fully established, and evidence is limited regarding the extended durability of the initial response.

---

What Is Still Uncertain About Гинофорт

A significant research gap is the limited amount of comparative evidence available. Head-to-head research comparing it directly against every other available treatment option is lacking. Furthermore, areas where certainty remains low include the long-term effects and research questions exploring cases where the infection recurs frequently. Evidence quality varies across studies, and future research will aim to provide more evidence in these areas of uncertainty.

Common questions about Гинофорт (FAQ)

Q: How soon can symptom relief be expected after using Гинофорт?

A: Official product information describes Гинофорт as a bioadhesive formulation designed for the sustained release of the active ingredient over a period of up to 72 hours. While studies track changes in patient-reported discomfort, regulatory documents do not specify a specific timeframe for the onset of symptom relief.

Q: Can Гинофорт be used during menstruation?

A: According to the official patient instructions, the use of other vaginal products, such as tampons and douches, is generally advised against during the course of treatment. Official guidance on avoiding other vaginal products suggests potential interference with the medicine's effectiveness.

Q: What is the difference between Гинофорт and other candidiasis creams?

A: The defining feature of Гинофорт is its formulation as a bioadhesive vaginal cream. This allows the medicine to be typically administered as a single dose. Its formulation is a bioadhesive system designed to adhere to the application site and provide a sustained release of the active ingredient over approximately 72 hours.

Q: What should be done if symptoms do not clear up after using Гинофорт?

A: Official regulatory information indicates that if symptoms continue after treatment, further evaluation is advised. This process may include further professional evaluation to rule out other pathogens or confirm the original diagnosis.

Q: Is a doctor's prescription needed to buy Гинофорт?

A: According to regulatory documentation in many regions, the product is labeled as Rx Only. This means that a prescription from a licensed healthcare provider is typically required for purchase.

Q: How long can Гинофорт be stored?

A: Official product information requires that the cream be stored at controlled room temperature, which is 25 C (77 F), while avoiding freezing. The specific shelf-life (expiration date) is always determined by the manufacturer and is printed on the packaging.

Q: What should be done if the time to use Гинофорт was missed?

A: Гинофорт is designed to be administered as a single dose. Because of this single-application protocol, the regulatory labeling does not include instructions regarding a daily dosing schedule or what to do for a missed dose.

Q: Is Гинофорт used to treat other infections besides candidiasis?

A: Official regulatory indications specify that this medicine is approved only for the local treatment of vulvovaginal candidiasis, which is commonly known as a yeast infection caused by Candida species.

Q: What should be done if a small amount of Гинофорт was accidentally swallowed?

A: The regulatory labeling strictly states that the cream is for vaginal use only and is not intended to be taken by mouth. The active component, Butoconazole Nitrate, is classified with warnings indicating that it should not be ingested.

Q: Can Гинофорт be used if there is an allergy to other antifungal agents?

A: The official contraindications for Гинофорт are limited to patients with a known history of hypersensitivity or allergy only to the active ingredient, butoconazole nitrate, or any of the non-medicinal components in the product.

Q: Does Гинофорт affect gut flora?

A: Гинофорт is a topical drug for local intravaginal use. Studies show that systemic absorption of the active ingredient is minimal, around 1.7% of the dose on average. Given its local mechanism and minimal systemic absorption, official regulatory guidance does not address an effect on gut microflora.

Q: Can Гинофорт cause menstrual cycle disturbance?

A: Official adverse reaction lists include local site reactions like burning, itching, and pelvic or abdominal cramping as common side effects. However, regulatory documents do not list menstrual cycle disturbance as a documented adverse reaction to the product.

Q: What are the general expectations from using Гинофорт?

A: The primary expectation is for the medicine to treat the fungal infection (vulvovaginal candidiasis). The active ingredient works through fungicidal action against the Candida species, which aims to destroy or inhibit fungal cells and reduce associated symptoms.

Q: Are there hormones in Гинофорт's composition?

A: The only active ingredient in Гинофорт is Butoconazole Nitrate, which is classified as an Azole Antifungal. Official regulatory descriptions classify the medicine as an anti-infective and antiseptic, confirming that it is not a hormone-containing product.

Q: Does Гинофорт affect the ability to drive a car?

A: Due to the drug's localized, intravaginal route of administration and minimal systemic absorption, official regulatory labeling typically does not include specific warnings about impairment to the ability to drive or operate machinery.

Q: Can Гинофорт be used for prevention?

A: According to the official indications and usage documentation, the medicine is approved for the treatment of vulvovaginal candidiasis. It is not indicated or approved by regulatory bodies for use as a preventative (prophylactic) measure.

Q: Can Гинофорт cause a headache?

A: Official regulatory information lists common side effects that are primarily localized to the application area, such as burning, itching, and pelvic discomfort. Headache is not listed among the most commonly reported adverse reactions documented in the regulatory label.

Q: Are there restrictions on physical activity after applying Гинофорт?

A: Patient instructions generally advise against using certain vaginal products, such as tampons and douches, while using the medication. Instructions advise against using certain products that may interfere with treatment, which serves as general guidance related to activities that could dislodge the cream.

Q: Does the use of Гинофорт affect the restoration of normal microflora?

A: The active component is fungicidal, meaning it targets and eliminates Candida species. Official regulatory guidance focuses on the drug's effect against Candida species and does not specifically discuss its effect on the restoration of beneficial bacterial microflora.

Q: Is it necessary to restrict sexual activity while using Гинофорт?

A: Official patient instructions advise avoiding sexual intercourse and the use of other vaginal products, such as tampons or douches, while using the medication and for a period following application. This restriction is based on instructions to avoid activity that may interfere with the medication's local action and integrity.

How to Store and Dispose of Гинофорт?

Гинофорт (Butoconazole Nitrate) must be stored at a controlled room temperature of 25 C (77 F), with permitted temperature excursions between 15 C and 30 C (59 F and 86 F). The product must not be frozen.

The medication must be kept in its original, tightly closed container and must be stored out of the reach of children. Use is prohibited if the protective foil over the applicator is found to be broken or missing.

For disposal, unused or expired Butoconazole Nitrate cream must not be flushed down a toilet or poured into a drain unless specifically instructed by a healthcare professional. Disposal must follow the instructions provided by a pharmacist or local waste disposal company.